To “C” Or Not To “C:” Can High Dose Vitamin “C” Impact Side Effects of Chemotherapy?

by Vicky Rego, Breast Cancer Helpline Coordinator

I recently had the opportunity to attend the Breast Cancer Options Integrative Medicine conference at SUNY New Paltz, where there were several workshops discussing topics such as risk and recurrence reduction, medical marijuana in treatment and care, a report back from San Antonio lead by Dr. Sheldon Feldman, stress reduction, nutrition, the financial impact of cancer, and moving beyond BRCA genetic testing.

Ovarian Cancer Research News from SGO 2019

This month gynecologic oncologists from across the country got together to share their research at the Society of Gynecologic Oncology Conference (SGO). We were inspired to see so many leading experts working hard to find better treatments for ovarian cancer. We’ve linked to several articles published in the oncology media about the conference so you can learn more.

FDA Approves Genentech’s Avastin® (Bevacizumab) Plus Chemotherapy as a Treatment for Women with Advanced Ovarian Cancer Following Initial Surgery

Avastin is now approved for ten distinct uses across six different types of cancer in the United States.

SOUTH SAN FRANCISCO, Calif. – June 13, 2018 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Avastin® (bevacizumab) in combination with chemotherapy (carboplatin and paclitaxel), followed by Avastin as a single agent, for the treatment of women with advanced (stage III or IV) ovarian cancer following initial surgical resection.

Most Early-Stage Breast Cancer Patients Can Safely Avoid Chemotherapy, According to Landmark TAILORx Results Presented at ASCO 2018 and Published in The New England Journal of Medicine

Seventy percent of early-stage breast cancer patients can safely forego
chemotherapy and use hormonal therapy alone (such as Arimidex®, tamoxifen or
Faslodex®), according to the long-awaited results of the landmark TAILORx (Trial
Assigning IndividuaLized Options for Treatment (Rx)) study presented at the 2018
American Society of Clinical Oncology (ASCO) Annual Meeting on June 3. The
largest-ever breast cancer treatment study, TAILORx is a prospective, randomized
clinical trial sponsored by the NCI and designed to more precisely define the
effect of chemotherapy for women with Oncotype DX Breast Recurrence Score®

Treating Endocrine-Resistant Metastatic Breast Cancer

In September, the FDA approved amebaciclib (Verzenio), the latest drug to treat endocrine resistant metastatic breast cancer (MBC). In combination with fulvestrant (Faslodex), the results of the phase III, Monarch 2 trial showed an improvement in progression free survival (PFS). All the patients in the trial were hormone receptor positive and HER2 negative, as are all the enrollees in the trials noted here.

Update on TAPUR Study

At its annual meeting this year in June, the American Society of Clinical Oncology (ASCO) gave patient advocates an update on the TAPUR clinical trial, which is its first trial. The trial was rolled out about two years ago.

The TAPUR trial (Targeted Agent and Profiling Utilization Registry) allows us to obtain FDA-approved drugs free-of-charge by cutting out the red tape when we are no longer benefiting from any standard treatment.